Answer
In healthy volunteers, ketoconazole (400 mg daily for 27 days), a strong CYP3A4 inhibitor, increased single-dose cabozantinib plasma exposure (AUC) by 38% and decreased clearance by 29%, so co-administration requires caution.
Sources for this answer
- COMETRIQ 20 & 80 mg hard capsulesIpsen Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 15Document updated
Sources checked